Regular physical activity lowers cancer risk, aids recovery and improves survival. In this expert-led interview, we explore ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Researchers have identified ways in which chemotherapy can damage healthy cells and found that some drugs can add decades of ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Fresenius announced that its operating company, Fresenius Kabi, has introduced two new biosimilars – Conexxence ...

Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® ...

Accurate brain tumors segmentation is essential for precise diagnosis, planning, treatment, and monitoring of the tumor. However, the variations in tumor size, shape, and location, automating this ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...